BNTC
Benitec Biopharma Inc. NASDAQ Listed Jun 24, 2014$10.02
After hrs
$10.02
+0.00%
Mkt Cap $344.2M
52w Low $9.26
10.2% of range
52w High $16.76
50d MA $12.16
200d MA $11.98
P/E (TTM)
—
EV/EBITDA
—
P/B
3.7x
Debt/Equity
0.0x
ROE
-5.9%
P/FCF
-14.7x
RSI (14)
11.10
ATR (14)
$0.74
Beta
0.12
50d MA
$12.16
200d MA
$11.98
Avg Volume
160.4K
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
3940 Trust Way · Hayward, CA 94545 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | BMO | -0.26 | -0.26 | +1.6% | 12.19 | +0.4% | -0.9% | -8.5% | -0.1% | +2.9% | -3.0% | — |
| May 14, 2026 | BMO | -0.27 | -0.24 | +11.1% | 11.65 | -0.9% | +1.7% | -3.0% | -5.2% | -1.6% | +2.5% | — |
| Feb 12, 2026 | BMO | -0.23 | -0.26 | -13.0% | 11.34 | +0.4% | -8.5% | -0.2% | +2.0% | +2.6% | -1.8% | — |
| Nov 14, 2025 | BMO | -0.35 | -0.22 | +37.1% | 13.16 | +1.1% | +2.8% | +0.0% | -3.2% | +0.3% | +0.9% | — |
| Sep 22, 2025 | BMO | -0.28 | -0.42 | -50.0% | 13.51 | -1.1% | -2.1% | +6.6% | -2.1% | -0.7% | +2.1% | — |
| May 14, 2025 | BMO | -0.36 | -0.24 | +33.3% | 13.58 | -1.9% | -0.6% | +0.7% | +2.8% | -0.4% | -1.9% | — |
| Feb 14, 2025 | BMO | -1.00 | -0.36 | +64.0% | 11.25 | +1.5% | +0.1% | -0.6% | +3.4% | -2.3% | -6.8% | — |
| Nov 14, 2024 | BMO | -0.55 | -0.48 | +12.7% | 10.40 | -0.9% | +2.7% | -10.3% | +3.1% | +7.9% | -4.3% | — |
| Sep 26, 2024 | BMO | -0.49 | -1.32 | -169.4% | 8.79 | -1.9% | +5.0% | -0.4% | +19.5% | -7.1% | -3.8% | — |
| May 13, 2024 | BMO | -0.78 | -1.64 | -110.3% | 8.12 | +1.2% | +3.8% | +5.0% | +7.0% | +0.2% | +10.3% | — |
| Feb 13, 2024 | BMO | -0.39 | -2.64 | -576.9% | 2.85 | -1.4% | -1.8% | +2.9% | +3.5% | -0.7% | +22.6% | — |
| Nov 13, 2023 | BMO | -0.51 | -2.76 | -441.2% | 3.46 | +2.9% | +6.4% | +4.9% | -7.0% | -4.5% | +2.6% | — |
| Sep 21, 2023 | BMO | -3.23 | -2.83 | +12.4% | 2.95 | +8.5% | +3.4% | +3.3% | +0.0% | -5.4% | +3.0% | — |
| May 15, 2023 | AMC | -0.20 | -2.72 | -1260.0% | 3.64 | +0.5% | +1.9% | -12.9% | +3.7% | +4.5% | -2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 28 | Wedbush | Initiates | Outperform | $16 | $11.58 | $12.18 | +5.2% | +2.7% | +1.3% | -1.6% | -1.3% | +3.8% |
| Jun 10 | Guggenheim | Downgrade | Buy → Neutral | — | $10.81 | $10.20 | -5.6% | -3.9% | +6.4% | +1.2% | +1.3% | -2.0% |
| May 12 | Evercore ISI | Initiates | Outperform | $25 | $12.08 | $12.07 | -0.1% | -2.0% | -1.6% | +1.7% | -3.0% | -5.2% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.34 | $11.34 | +0.0% | +10.7% | -2.2% | +0.1% | -1.3% | -3.1% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.26 | $13.29 | +0.2% | -1.4% | -1.1% | +0.7% | -0.5% | -5.6% |
| Nov 4 | Citizens | Maintains | Market Outperform → Market Outperform | — | $15.86 | $15.33 | -3.3% | -0.9% | +0.4% | -24.0% | +6.6% | +0.8% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.86 | $15.33 | -3.3% | -0.9% | +0.4% | -24.0% | +6.6% | +0.8% |
| Sep 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $13.22 | $13.12 | -0.8% | +6.6% | -2.1% | -0.7% | +2.1% | +0.3% |
| Sep 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.70 | $13.66 | -0.3% | +1.6% | -1.6% | +2.1% | -3.9% | +0.4% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.60 | $13.48 | -0.9% | +2.8% | -0.4% | -1.9% | -0.6% | -2.9% |
| May 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $13.58 | $13.32 | -1.9% | -0.6% | +0.7% | +2.8% | -0.4% | -1.9% |
| Apr 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $12.17 | $12.07 | -0.8% | -1.9% | +5.8% | +5.1% | +3.1% | -0.2% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.11 | $16.51 | +2.5% | -11.0% | +2.3% | -4.5% | -2.0% | -2.2% |
| Mar 18 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $15.34 | $15.30 | -0.3% | +1.2% | +0.9% | +7.2% | -4.0% | -11.0% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.57 | $11.79 | +1.9% | -2.3% | -6.8% | +0.2% | +2.0% | +6.0% |
| Dec 3 | Guggenheim | Maintains | Buy → Buy | — | $9.76 | $9.75 | -0.1% | +2.5% | -1.5% | -0.7% | +14.8% | +8.5% |
| Apr 22 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.99 | $7.14 | +2.1% | -3.9% | +2.1% | -2.0% | +3.3% | -0.6% |
| Feb 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.80 | $3.00 | +7.1% | +2.9% | +3.5% | -0.7% | +22.6% | +0.3% |
| Jan 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.89 | $2.91 | +0.7% | -1.4% | +3.2% | +4.4% | -1.6% | -3.3% |
| Sep 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.15 | $3.07 | -2.5% | +0.0% | -5.4% | +3.0% | -1.6% | +0.6% |
| Jun 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.38 | $5.05 | +49.4% | +81.1% | -25.0% | -7.4% | -5.2% | +0.7% |
| Jun 25 | JMP Securities | Maintains | Market Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| May 18 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.23 | $3.23 | +0.0% | +3.7% | +4.5% | -2.9% | +5.0% | -0.8% |
| May 18 | JMP Securities | Maintains | Market Outperform → Outperform | — | $3.23 | $3.23 | +0.0% | +3.7% | +4.5% | -2.9% | +5.0% | -0.8% |
| May 17 | JMP Securities | Maintains | Market Outperform → Outperform | — | $3.71 | $3.66 | -1.3% | -12.9% | +3.7% | +4.5% | -2.9% | +5.0% |
| Oct 18 | JMP Securities | Maintains | Market Outperform → Outperform | — | $4.01 | $5.01 | +24.9% | -2.5% | -10.0% | -3.4% | +0.9% | -6.4% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.53 | $5.53 | +0.0% | -1.3% | -2.9% | +2.3% | +7.6% | +3.6% |
| Feb 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.68 | $49.30 | +7.9% | -3.6% | -1.5% | -0.6% | -3.4% | -3.3% |
| Nov 25 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $45.73 | $46.41 | +1.5% | +5.2% | +3.9% | +0.7% | -3.4% | -1.4% |
| Oct 5 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $51.51 | $53.55 | +4.0% | +5.6% | -4.1% | +1.3% | -1.9% | +1.6% |
No insider trades available.
8-K · 2.02
!! High
Benitec Biopharma Inc. -- 8-K 2.02: Earnings Results
Sep 14
8-K · 5.02
!!! Very High
Benitec Biopharma Inc. -- 8-K 5.02: Executive Change
May 29
8-K · 2.02
!! High
Benitec Biopharma Inc. -- 8-K 2.02: Earnings Results
May 14
8-K
Benitec Biopharma Inc. -- 8-K Filing
Benitec Biopharma filed its quarterly 10-Q report with the SEC, providing investors with updated financial statements and operational disclosures required for public company compliance.
Feb 12
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 7
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Small Cap Index Fund | 11,064 | $148K | Jun 2026 |
| 2 | Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF | 7,730 | $89K | May 2026 |
| 3 | Goldman Sachs Small Cap Growth Insights Fund | 6,026 | $73K | Jan 2026 |
| 4 | Penn Series Small Cap Index Fund | 500 | $5K | Mar 2026 |
| 5 | Russell 2000 Fund | 34 | $362 | Mar 2026 |
| 6 | Russell 2000 1.5x Strategy Fund | 20 | $213 | Mar 2026 |
| 7 | Russell 2000(R) 1.5x Strategy Fund | 6 | $80 | Jun 2026 |
Valuation
Market Cap
$344.2M
Enterprise Value
$249.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.18x
P/B
3.73x
P/S
—
P/FCF
-14.71x
EV/EBITDA
—
Shares Out
36.2M
Financials (TTM)
Revenue
$0
Net Income
-$45.5M
EBITDA
-$50.7M
Free Cash Flow
-$23.6M
Op Cash Flow
-$23.6M
EPS Basic
$-1.05
EPS Diluted
$-0.98
EPS Forward
$-1.13
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$99.6M
Total Liab.
$2.3M
Total Equity
$97.3M
Cash
$97.7M
LT Debt
$0
Book Value/Sh
$2.69
Debt/Equity
0.01x
Current Ratio
54.67
Quick Ratio
54.67
Returns & Growth
ROE
-5.9%
ROA
-5.8%
ROIC
-42.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
+60.8%
Price Returns
2W
-21.3%
1M
-25.5%
3M
-22.5%
6M
-11.3%
12M
-30.0%
Technicals
52W High
$16.76
52W Low
$9.26
50d MA
$12.16
200d MA
$11.98
RSI (14)
11.10
ATR (14)
$0.74
Beta
0.12
Avg Volume
160K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$27.00
High
$32.00
Low
$22.00
Median
$27.00
Data updated apr 24, 2026 10:23pm
· Source: financialmodelingprep.com